But semaglutide only activates the hormone GLP-1, while tirzepatide boosts GLP-1 and the hormone GIP.
The drugs dual action seems to explain its higher potency in terms of weight loss.
And both drugs so far appear to be generally safe and tolerated.
Eli Lilly’s Zepbound is taken via subcutaneous injection once a week.Image: oleschwander (Shutterstock)
It involved 670 people who were overweight or obese but had no diabetes at the start of the study.
Before the switch, people experienced an average 20.9% weight loss.
The results are not surprising.
Similar studies of semaglutide havefoundthe same rebound effect once people were taken off the drug.
But these findings might complicate the potential benefits offered by these newer medications, at least indirectly.
News from the future, delivered to your present.
Does Ozempic Really Cause Thyroid Cancer?
Ozempic Not Working for You?
